Overview

A Clinical Trial for Evaluation of Adequate Dose and Safety of DW-3102 in Hypercholesterolemia Patients

Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate adequate-dose of DW-3102 in the treatment of hypercholesterolemia patients by conducting phase 2a. 4 groups involving placebo group, each groups are composed by 16, will be participated in this trial.
Phase:
Phase 2
Details
Lead Sponsor:
Daewon Pharmaceutical Co., Ltd.